Most Semaglutide formulations, such as Ozempic and Wegovy, are given once weekly, on the same day each week, with or without meals
Switching between peptide therapies is possible under medical supervision
Not all GLP-1s are approved for obesity treatment, and this analysis includes all FDA-approved GLP-1s, including those approved for obesity (Saxenda, Weogvy, Zepbound) as well as those approved for type 2 diabetes (see Table 1)
They require gradual escalation of dosing, well-documented side effects and when stopped, participants tend to put their weight back on
It can be a temporary or a permanent condition
NHS access to these medicines is subject to NICE eligibility criteria, which typically include BMI thresholds, the presence of weight-related comorbidities, and involvement of a specialist weight management service